The efficacy of low-dose fluvoxamine compared with placebo for treating mild to moderate COVID-19 in the US JAMA_current WeillCornell DukeU UMNews JohnsHopkins COVID19 coronavirus covid SARSCoV2
By Pooja Toshniwal PahariaJan 18 2023Reviewed by Danielle Ellis, B.Sc. In a recent study published in JAMA, researchers evaluated the efficacy of low-dosage fluvoxamine over 10.0 days in the management of mild and moderate-severe acute respiratory syndrome coronavirus 2 infections in the United States .
About the study In the present randomized clinical trial study, researchers tested repurposed medications in outpatient settings for mild or moderate SARS-CoV-2 infections that do not require hospitalization. The prime outcome comprised the duration for sustained COVID-19 recovery . There were seven secondary study outcomes, inclusive of a composite study outcome comprising hospitalizations, urgent care visits, emergency department visits, or deaths within 28 days.
Regression models, including proportional hazards regression, were used for the analysis, and hazard ratios were calculated. Estimator variables included sex, age, symptom duration before receiving fluvoxamine, calendar time, the status of COVID-19 vaccination status, and place of residence. The median durations for sustained COVID-19 recovery were 12.0 days and 13.0 days for fluvoxamine-treated and placebo-treated individuals, respectively, with an HR value of 1.0. For the secondary composite study outcome, 26 fluvoxamine recipients were admitted to hospitals, hospitalized, required urgent care, visited the emergency department, or deceased, compared to 23 placebo recipients .
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
S. aureus enhances replication of SARS-CoV-2 in vitro through the bacterial iron-regulated surface determinant protein AS. aureus enhances replication of SARS-CoV-2 in vitro through the bacterial iron-regulated surface determinant protein A WesternU SARSCoV2 bacteria virus covid coronavirus covid
Read more »
Researchers reveal genetic predisposition to immunity against new variants of COVID-19The SARS-CoV-2 delta variant that caused the third wave of COVID-19 in mid-2021 turned out to be more contagious than earlier SARS-CoV-2 variants. In addition, protein mutations in the delta variant were found to significantly reduce the effect of acquired humoral immunity to COVID-19 from prior infection or vaccination.
Read more »
Researchers report that vectored expression of a high-affinity ACE2 microbody protein establishes a high degree of protection from SARS-CoV-2Researchers report that vectored expression of a high-affinity ACE2 microbody protein establishes a high degree of protection from SARS-CoV-2 biorxivpreprint nyugrossman ACE2 SARSCoV2 coronavirus covid
Read more »
Haemorrhage of human foetal cortex associated with SARS-CoV-2 infectionMassimo et al. report the presence of SARS-CoV-2 in first and second trimester foetal brain tissue in association with cortical haemorrhages. The haemorrhages w
Read more »
Overall patterns of SARS-CoV-2 caused by variants of concern among children and adolescentsOverall patterns of SARS-CoV-2 caused by variants of concern among children and adolescents medrxivpreprint UniBasel_en unibern institutpasteur sheffielduni SARSCoV2 covid coronavirus covid variantsofconcern childhealth teenagers
Read more »
Baby death rates increasing among poorest Scots, researchers findNew research finds that health inequalities are growing and average life expectancy is falling.
Read more »